RU2499592C2 - Фармацевтическая композиция для лечения ушных заболеваний - Google Patents

Фармацевтическая композиция для лечения ушных заболеваний Download PDF

Info

Publication number
RU2499592C2
RU2499592C2 RU2010147298/15A RU2010147298A RU2499592C2 RU 2499592 C2 RU2499592 C2 RU 2499592C2 RU 2010147298/15 A RU2010147298/15 A RU 2010147298/15A RU 2010147298 A RU2010147298 A RU 2010147298A RU 2499592 C2 RU2499592 C2 RU 2499592C2
Authority
RU
Russia
Prior art keywords
composition according
active substance
modulator
composition
antagonist
Prior art date
Application number
RU2010147298/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010147298A (ru
Inventor
Джей ЛИХТЕР
Бенедикт ФОЛЛЬРАТ
Эндрю М. ТРЭММЕЛ
Сергио Г. ДЮРОН
Фабрис ПЬЮ
Луис А. ДЕЛЛАМЭРИ
Цян Е
Карл ЛЕБЕЛ
Майкл Кристофер СКАЙФ
Джеффри П. ХАРРИС
Original Assignee
Отономи, Инк.
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Отономи, Инк., Дзе Регентс Оф Дзе Юниверсити Оф Калифорния filed Critical Отономи, Инк.
Publication of RU2010147298A publication Critical patent/RU2010147298A/ru
Application granted granted Critical
Publication of RU2499592C2 publication Critical patent/RU2499592C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2010147298/15A 2008-04-21 2009-04-21 Фармацевтическая композиция для лечения ушных заболеваний RU2499592C2 (ru)

Applications Claiming Priority (43)

Application Number Priority Date Filing Date Title
US4654308P 2008-04-21 2008-04-21
US61/046,543 2008-04-21
US4887808P 2008-04-29 2008-04-29
US61/048,878 2008-04-29
US12771308P 2008-05-14 2008-05-14
US61/127,713 2008-05-14
US5562508P 2008-05-23 2008-05-23
US61/055,625 2008-05-23
US6042508P 2008-06-10 2008-06-10
US61/060,425 2008-06-10
US7371608P 2008-06-18 2008-06-18
US61/073,716 2008-06-18
US7458308P 2008-06-20 2008-06-20
US61/074,583 2008-06-20
US7657608P 2008-06-27 2008-06-27
US7656708P 2008-06-27 2008-06-27
US61/076,567 2008-06-27
US61/076,576 2008-06-27
US8245008P 2008-07-21 2008-07-21
US61/082,450 2008-07-21
US8383008P 2008-07-25 2008-07-25
US8387108P 2008-07-25 2008-07-25
US61/083,871 2008-07-25
US61/083,830 2008-07-25
US8609408P 2008-08-04 2008-08-04
US8610508P 2008-08-04 2008-08-04
US61/086,105 2008-08-04
US61/086,094 2008-08-04
US8795108P 2008-08-11 2008-08-11
US8790508P 2008-08-11 2008-08-11
US61/087,951 2008-08-11
US61/087,905 2008-08-11
US8827508P 2008-08-12 2008-08-12
US61/088,275 2008-08-12
US9438408P 2008-09-04 2008-09-04
US61/094,384 2008-09-04
US10111208P 2008-09-29 2008-09-29
US61/101,112 2008-09-29
US14003308P 2008-12-22 2008-12-22
US61/140,033 2008-12-22
US16023309P 2009-03-13 2009-03-13
US61/160,233 2009-03-13
PCT/US2009/041320 WO2009132050A2 (en) 2008-04-21 2009-04-21 Auris formulations for treating otic diseases and conditions

Publications (2)

Publication Number Publication Date
RU2010147298A RU2010147298A (ru) 2012-05-27
RU2499592C2 true RU2499592C2 (ru) 2013-11-27

Family

ID=41217397

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010147298/15A RU2499592C2 (ru) 2008-04-21 2009-04-21 Фармацевтическая композиция для лечения ушных заболеваний

Country Status (13)

Country Link
US (8) US9132087B2 (cg-RX-API-DMAC7.html)
EP (1) EP2278999B1 (cg-RX-API-DMAC7.html)
JP (6) JP2011518195A (cg-RX-API-DMAC7.html)
KR (6) KR20160029870A (cg-RX-API-DMAC7.html)
CN (2) CN102014957B (cg-RX-API-DMAC7.html)
AU (1) AU2009239429B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910850B1 (cg-RX-API-DMAC7.html)
CA (1) CA2721927C (cg-RX-API-DMAC7.html)
HK (1) HK1209055A1 (cg-RX-API-DMAC7.html)
IL (2) IL208549A (cg-RX-API-DMAC7.html)
MX (1) MX2010011545A (cg-RX-API-DMAC7.html)
RU (1) RU2499592C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009132050A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2551359C1 (ru) * 2013-11-28 2015-05-20 Олег Ростиславович Михайлов Наноразмерная слабо закристаллизованная модификация 4-метил-n-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2751697C1 (ru) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Средство для лечения отитов наружного слухового прохода у собак

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
GB2461962B (en) * 2008-07-25 2011-02-16 Otonomy Inc Slow release NMDA receptor antagonist for otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CN102159209A (zh) * 2008-08-11 2011-08-17 奥克兰联合服务有限公司 听力缺失的治疗
CA2751761A1 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
US8987328B2 (en) * 2008-10-30 2015-03-24 Trinity Laboratories, Inc. Esters of capsaicinoids as dietary supplements
WO2010060088A2 (en) 2008-11-24 2010-05-27 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
CN106344495A (zh) * 2008-12-22 2017-01-25 奥德纳米有限公司 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物
EP2437772B1 (en) 2009-06-05 2017-12-06 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
CA2772097C (en) 2009-08-24 2019-04-30 Hough Ear Institute Methods for treating acute acoustic trauma
WO2011025771A1 (en) * 2009-08-25 2011-03-03 Biogen Idec Ma Inc. Compositions for delivery of insoluble agents
US20140076336A1 (en) * 2009-09-17 2014-03-20 Ascentia Health, Inc. Ear insert for relief of tmj discomfort and headaches
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
CN102008470B (zh) * 2010-05-24 2012-08-29 中国人民解放军第二军医大学 复方制剂及其预防和治疗噪声性听力损伤的用途
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
WO2011156631A2 (en) * 2010-06-09 2011-12-15 Joule Unlimited Technologies, Inc. Methods and compositions to extract carbon-based products from host cells
DE102010030053A1 (de) * 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
WO2011157449A1 (en) * 2010-06-18 2011-12-22 Merz Pharma Gmbh & Co. Kgaa Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives
KR101134622B1 (ko) * 2010-08-12 2012-04-09 한국원자력연구원 암포테리신 b의 서방성 수화겔 및 이의 제조방법
WO2012037117A1 (en) 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
EP3501521A1 (en) * 2011-02-18 2019-06-26 Otonomy, Inc. Prevention of and recovery from drug-induced ototoxicity
JP2014507441A (ja) * 2011-02-25 2014-03-27 エイド・ファルマ 単独で、または抗生物質と共に感染症を予防または治療するための精油のナノカプセル化
US8580748B2 (en) * 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
CN102805896A (zh) * 2011-05-30 2012-12-05 惠觅宙 经皮给药方法、制剂和系统
US9193704B2 (en) * 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
RU2480214C1 (ru) 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
US20140341940A1 (en) * 2011-11-09 2014-11-20 Iseu da Silva Nunes Immunomodulator for the treatment of cancerous tumors in the epithelial tissue lining surfaces inside or outside body organs
WO2013090452A1 (en) 2011-12-12 2013-06-20 Orbis Biosciences, Inc. Sustained release particle formulations
US9034347B2 (en) * 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2013124416A1 (en) * 2012-02-23 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
EP2819741B1 (en) * 2012-02-27 2018-03-28 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
US20130288981A1 (en) * 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
EP2872128B1 (en) * 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
EP2892506B1 (en) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
JP6579956B2 (ja) 2012-11-28 2019-09-25 アフィオス コーポレーション 神経変性疾患および他の疾患の治療のための併用治療薬および方法
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
CN110420316A (zh) 2013-06-18 2019-11-08 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点
CN105682742A (zh) 2013-08-27 2016-06-15 奥德纳米有限公司 小儿耳部病症的治疗
EP2853533A1 (de) * 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
WO2015126192A1 (ko) * 2014-02-20 2015-08-27 아주대학교산학협력단 시스테인 류코트리엔 수용체 길항제 및 은행잎 추출물을 포함하는 감각신경성 난청의 치료 또는 예방용 약학 조성물
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
EP3139744A4 (en) * 2014-04-23 2017-12-20 Auris Medical AG Methods and compositions for treating and preventing tinnitus
US10010585B2 (en) * 2014-06-16 2018-07-03 Massachusetts Eye And Ear Infirmary Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
CN107073042A (zh) * 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
TW201625232A (zh) * 2014-10-01 2016-07-16 陳建宏 含有阿司匹靈、二甲雙胍和血清素與非離子界面活性劑的醫藥組合物
DK3256850T3 (da) * 2015-02-09 2025-08-18 Slingshot Biosciences Inc Hydrogelpartikler med justerbare optiske egenskaber og fremgangsmåder til anvendelse deraf
PE20180021A1 (es) 2015-02-20 2018-01-09 Univ Oregon Health & Science Derivados de sobetiroma
KR101636733B1 (ko) * 2015-02-24 2016-07-07 인제대학교 산학협력단 에키노크롬 a를 유효성분으로 함유하는 운동능력 증진용 건강식품 및 이를 이용한 운동능력 증진방법
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
EP3328898B8 (en) * 2015-07-28 2024-04-10 6452728 Canada Corp. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
MX388197B (es) * 2015-08-21 2025-03-19 Hoffmann La Roche Método para la reducción de proteínas de células hospederas en cromatografía de afinidad.
EP3368553B1 (en) * 2015-10-27 2023-08-02 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
US20170128424A1 (en) * 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
WO2017147221A1 (en) * 2016-02-26 2017-08-31 Med-El Elektromedizinische Geraete Gmbh Detection of electrically evoked stapedius reflex
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
KR101785455B1 (ko) * 2016-03-16 2017-11-20 전남대학교산학협력단 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물
CN109310695B (zh) 2016-04-21 2022-04-01 阿斯特罗赛特制药公司 治疗神经和心血管病况的化合物和方法
EP3478269A4 (en) * 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
US20190254997A1 (en) * 2016-07-21 2019-08-22 The Regents Of The University Of California Methods for inducing stereocilia on hair cells
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. OTIC GEL FORMULATIONS FOR THE TREATMENT OF EXTERNAL OTITIS
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
US10576125B2 (en) 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
US11253193B2 (en) * 2016-11-08 2022-02-22 Cochlear Limited Utilization of vocal acoustic biomarkers for assistive listening device utilization
WO2018094262A2 (en) * 2016-11-18 2018-05-24 Mayo Foundation For Medical Education And Research Materials and methods for treating regional pain
EP3554487A4 (en) * 2016-12-13 2020-10-21 The Regents of The University of California XENOBIOTIC FREE CULTURE SYSTEM TO GROW HUMAN LIMBIC STEM CELLS
RU2630129C1 (ru) * 2016-12-19 2017-09-05 Государственное бюджетное учреждение здравоохранения города Москвы "Научно-исследовательский клинический институт оториноларингологии им. Л.И. Свержевского" Департамента здравоохранения города Москвы Способ определения степени эндолимфатического гидропса при болезни меньера, выбор тактики лечения и оценка ее эффективности
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
DK3698791T3 (da) * 2017-02-02 2024-01-15 Otolanum Ag Intranasal sammensætning, der omfatter betahistin
JP7167059B2 (ja) * 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
US12076415B2 (en) 2017-08-18 2024-09-03 King Fahd University Of Petroleum And Minerals Use of nano-sized clay crystallites to restore adhesion among tumor and aging stem cells
EP3691618A1 (en) 2017-10-06 2020-08-12 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
WO2019118330A1 (en) * 2017-12-12 2019-06-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
US11918653B2 (en) * 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
WO2019140012A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2019152110A1 (en) * 2018-01-31 2019-08-08 Kci Usa, Inc. Antimicrobial composition, dressing, dressing components, and method
US11839615B2 (en) 2018-02-09 2023-12-12 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders
BR112020016059A2 (pt) * 2018-02-09 2020-12-08 Decibel Therapeutics, Inc. Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina
JP6383133B1 (ja) * 2018-02-21 2018-08-29 国立大学法人信州大学 液体塞栓剤組成物
US20190307885A1 (en) * 2018-04-04 2019-10-10 Alivio Therapeutics, Inc. Self-assembled gels for controlled delivery of biologics and methods of making thereof
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants
KR102928295B1 (ko) 2018-09-07 2026-02-13 알.피.쉐러 테크놀러지즈 엘엘씨 경화 및 낮은 hlb 계면 활성제(들)의 첨가를 통한 고체 또는 반고체 지질 기반 제형 안정화
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020123866A1 (en) * 2018-12-12 2020-06-18 Curelator, Inc. System and method for detecting auditory biomarkers
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
EP3962533A4 (en) 2019-04-30 2023-01-25 The Medical College of Wisconsin, Inc. PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF
CN114174799A (zh) * 2019-05-30 2022-03-11 贝克曼库尔特有限公司 用于固定生物标本以进行显微成像的方法和系统
CN110101871B (zh) * 2019-05-30 2022-03-25 广东工业大学 一种包埋白藜芦醇的制备方法
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020254249A1 (en) * 2019-06-21 2020-12-24 Proqr Therapeutics Ii B.V. Delivery of nucleic acids for the treatment of auditory disorders
AU2019467888B2 (en) * 2019-09-24 2025-09-11 Halliburton Energy Services, Inc. Fragile and normal viscoelastic components of drilling fluid gels
WO2021092499A1 (en) * 2019-11-08 2021-05-14 Spiral Therapeautics, Inc. Treatments of meniere's disease
CN115279359A (zh) 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
BR112022013755A2 (pt) * 2020-01-13 2022-10-11 Astromedical Biotechnology Ltd Métodos para o tratamento de caquexia e de câncer, e, composição farmacêutica
WO2021151013A1 (en) * 2020-01-24 2021-07-29 Otonomy, Inc. Growth factor formulation for condition associated with otic event
CN115426991A (zh) 2020-01-24 2022-12-02 斯皮拉尔诊疗有限公司 用于治疗耳部疾病的装置、系统和方法
EP3854385A1 (en) 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
DK4114975T3 (da) * 2020-03-06 2026-06-15 Regeneron Pharma Fascin-2 (fscn2) variant og anvendelse deraf
AU2021235058A1 (en) * 2020-03-11 2022-09-01 Iterum Therapeutics International Limited Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
CA3177834A1 (en) 2020-05-04 2021-11-11 Jeffrey Kim Compositions and methods for passive optical barcoding for multiplexed assays
NL2025530B1 (en) * 2020-05-08 2021-11-23 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Fluid injection device
EP4149431A4 (en) * 2020-05-13 2024-05-29 Spiral Therapeutics Inc. GELLING SOLUTIONS FOR DELIVERY OF COMPOUNDS TO THE INNER EAR
RU2741252C1 (ru) * 2020-06-01 2021-01-22 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ выбора метода хирургического лечения пациентов с болезнью меньера
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
KR20240127867A (ko) * 2020-08-10 2024-08-23 지로파, 인코포레이티드 국소 전달을 위한 조성물 및 방법
CA3190833A1 (en) * 2020-08-26 2022-03-03 Michael Mcdonald CROWLEY Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation
WO2022047234A1 (en) * 2020-08-28 2022-03-03 President And Fellows Of Harvard College Drug combination kits and methods of drug delivery
CN112618571B (zh) * 2020-09-30 2023-04-07 杭州贤石生物科技有限公司 治疗骨科疾病的可注射水凝胶微球及其制备方法与应用
CN112125969A (zh) * 2020-09-30 2020-12-25 东南大学 生物因子rimbp2在维持内耳毛细胞特性上的应用
EP4251127A1 (en) 2020-11-26 2023-10-04 Alain Moussy Pharmaceutical composition for treatment of inner ear disorders through local administration in the tympanic area
CN112557158B (zh) * 2021-02-28 2021-05-28 中国工程物理研究院核物理与化学研究所 一种用于空气样品中氙的分离纯化收集装置
WO2022231076A1 (ko) * 2021-04-30 2022-11-03 서울대학교병원 감각신경성 난청의 원인 특이적 치료 효과 예측 방법 및 이에 사용되는 진단 키트
AU2022271304A1 (en) 2021-05-06 2023-11-23 Autobahn Therapeutics, Inc. Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors
CN113425852B (zh) * 2021-05-24 2022-06-03 北京大学 一种可穿过血迷路屏障的偶联物及其制备方法
CN113456580B (zh) * 2021-07-21 2024-03-22 沈阳化工大学 一种白藜芦醇原位凝胶制备及其表征方法
KR102675908B1 (ko) 2021-09-03 2024-06-14 충남대학교산학협력단 내이 질환 치료를 위한 국소 약물전달용 나노입자 함유 하이드로겔 조성물 및 이의 제조방법
JP2024539956A (ja) 2021-10-29 2024-10-31 スリングショット バイオサイエンシーズ, インコーポレイテッド フィーダー細胞としておよび合成抗原提示細胞としてのヒドロゲル粒子
DK4452267T3 (da) * 2021-12-23 2025-05-26 Cilcare Dev 4-phenyl-tetrahydropyridinderivater til behandling af hørelidelser
CA3243960A1 (en) * 2022-02-09 2023-08-17 Interlude Biopharma Co. RHO KINASE INHIBITION COMPOSITIONS AND METHODS
AU2023265684A1 (en) 2022-05-05 2024-11-21 Slingshot Biosciences, Inc. Engineered particles as red blood cell mimics and compositions containing same for hematology
WO2023230430A1 (en) * 2022-05-21 2023-11-30 Neuvision Development Llc Topical ocular administration of ambroxol for ocular pain
CA3257621A1 (en) 2022-06-02 2023-12-07 Slingshot Biosciences, Inc. APOPTOTIC CELL MIMETIC
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus
EP4316462A1 (en) * 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of bdnf for the treatment of sensorineural hearing loss
CN115317446A (zh) * 2022-09-01 2022-11-11 黑龙江迪龙制药有限公司 一种含有天麻素的复方制剂及其制备方法
WO2024092161A2 (en) 2022-10-26 2024-05-02 Slingshot Biosciences, Inc. Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation
WO2024148287A2 (en) * 2023-01-06 2024-07-11 Gateway Biotechnology, Inc. Combination therapies for treatment of hearing disorders
CN116019818B (zh) * 2023-01-18 2024-03-19 上海交通大学医学院附属第九人民医院 一种用于预防、改善和/或治疗耳蜗突触损伤的组合物及其应用
US12461007B2 (en) 2023-08-29 2025-11-04 Slingshot Biosciences, Inc. CD34 stem cell mimics
CN117448350B (zh) * 2023-10-18 2024-05-10 哈尔滨学院 一种利用桑黄Pb-bHLH9基因提高酿酒酵母多重胁迫抗性的应用
CN117860771B (zh) * 2024-01-15 2026-07-28 山东第一医科大学(山东省医学科学院) 黄豆苷在制备抗顺铂耳毒性药物中的应用
CN121891373B (zh) * 2026-03-24 2026-07-10 山东大学齐鲁医院 尼可霉素在制备治疗脂质沉积性肌病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107791B1 (en) * 1998-09-04 2007-05-30 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4474572A (en) 1981-09-29 1984-10-02 Syntex (U.S.A.) Inc. Implanting device and implant magazine
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4758435A (en) 1986-08-11 1988-07-19 American Cyanamid Company Estradiol implant composition and method for preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
AU6952391A (en) 1989-11-29 1991-06-26 Brigham And Women's Hospital (ala il-8)77 as a leukocyte adhesion inhibitor
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
IT1251151B (it) 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
EP0551626A1 (en) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6083354A (en) 1992-07-24 2000-07-04 Matsushita Electric Industrial Co., Ltd. Treatment method for diamonds
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ES2113094T3 (es) 1993-03-09 1998-04-16 Epic Therapeutics Inc Las microparticulas macromoleculares y metodos de obtencion.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
AU7376494A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
GB9505032D0 (en) 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
WO1997005185A2 (en) * 1995-07-28 1997-02-13 Focal, Inc. Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
FR2742750B1 (fr) 1995-12-22 1998-01-30 Oreal Nouveaux derives de l'acide l-2-oxothiazolidine 4-carboxylique et leur utilisation pour le soin de la peau
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US6379911B2 (en) 1996-02-23 2002-04-30 Albert Einstein College Of Medicine Of Yeshiva University Enzyme detection/assay method and substrates
US5929041A (en) 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
AU2676397A (en) 1996-04-18 1997-11-07 University Technology Corporation Methods for treating middle and inner ear disorders
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
DE69833000T2 (de) 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
KR20010031363A (ko) 1997-10-22 2001-04-16 젠스 포니카우 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도
DE19748763A1 (de) 1997-11-05 1999-05-06 Hans Peter Zenner Verwendung von Vasopressin-Antagonisten
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
WO2000007603A2 (en) 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US8197461B1 (en) 1998-12-04 2012-06-12 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
JP3572570B2 (ja) 1999-02-01 2004-10-06 オーテックス株式会社 カチオン重合性有機物質用の重合開始剤
PT1165564E (pt) 1999-04-08 2009-04-16 Einstein Coll Med Processo para a preparação de inibidores do metabolismo de nucleósidos
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6537540B1 (en) 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
HK1047582B (zh) 1999-06-23 2005-03-04 萨诺费-阿文蒂斯德国有限公司 取代的苯並咪唑
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2001072298A1 (en) * 2000-03-27 2001-10-04 The General Hospital Corporation Treatments for immune-mediated ear disorders
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US7289110B2 (en) * 2000-07-17 2007-10-30 Human Messaging Ab Method and arrangement for identifying and processing commands in digital images, where the user marks the command, for example by encircling it
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
WO2002018371A1 (en) 2000-08-29 2002-03-07 Industrial Research Limited Nucleoside metabolism inhibitors
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1328272A1 (en) 2000-10-12 2003-07-23 SmithKline Beecham Corporation Nf-kappa-b inhibitors
AU2002211663A1 (en) 2000-10-12 2002-04-22 Smith Kline Beecham Corporation Nf-$g(k)b inhibitors
CN1503673A (zh) 2000-10-26 2004-06-09 �㽭�пؼ����ɷ����޹�˾ 消炎药
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag 4−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
EP1370139A4 (en) 2001-01-04 2010-09-22 Einstein Coll Med INHIBITORS OF ADP-RIBOSYLTRANSFERASES, CYCLASES AND HYDROLASES AND THEIR USE
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
CZ20032287A3 (cs) 2001-02-01 2004-02-18 Bristol-Myers Squibb Company Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
US20060269602A1 (en) 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
WO2002094265A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
TWI324925B (en) 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
CA2460939C (en) 2001-09-19 2008-07-29 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
EP1444207A2 (en) 2001-09-19 2004-08-11 Pharmacia Corporation Substituted pyrazolyl-compounds for the treatment of inflammation
US7166639B2 (en) 2001-10-04 2007-01-23 Smithkline Beecham Corporation NF-κB inhibitors
CA2467854A1 (en) 2001-11-21 2003-06-05 Vern L. Schramm Sir2 products and activities
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
MXPA04005427A (es) 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
RS63204A (sr) 2002-01-17 2006-10-27 Neurogen Corporation Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
US20030229333A1 (en) 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
JP2003277383A (ja) 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
JP2005531574A (ja) 2002-05-22 2005-10-20 アムジエン・インコーポレーテツド 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
TW200410945A (en) 2002-08-08 2004-07-01 Amgen Inc Vanilloid receptor ligands and their use in treatments"
US7589110B2 (en) 2002-09-06 2009-09-15 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
US20060013858A1 (en) 2002-10-29 2006-01-19 Trune Dennis R Fludrocortisone treatment for hearing loss
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US8802116B2 (en) * 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
AU2003900887A0 (en) * 2003-02-27 2003-03-13 Novasel Australia Pty Ltd Poloxamer emulsion preparations
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
US7279499B2 (en) 2003-04-21 2007-10-09 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US20040247575A1 (en) 2003-06-03 2004-12-09 Caplice Noel M. Smooth muscle progenitor cells
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
EP1648878B9 (en) 2003-07-24 2011-03-16 Euro-Celtique S.A. Piperidine compounds and pharmaceutical compositions containing them
US7390907B2 (en) 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7700086B2 (en) 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
US20050137122A1 (en) 2003-12-17 2005-06-23 Alcon, Inc. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
JP2005220070A (ja) 2004-02-05 2005-08-18 Medgel Corp 神経再生および保護のための生体吸収性高分子ハイドロゲル製剤
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
EP1747215A1 (en) 2004-05-12 2007-01-31 Aventis Pharmaceuticals, Inc. Substantially pure 2-{¬2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl|-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor
WO2005115527A2 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060046970A1 (en) 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US8498681B2 (en) 2004-10-05 2013-07-30 Tomophase Corporation Cross-sectional mapping of spectral absorbance features
EA200700807A1 (ru) 2004-10-05 2007-08-31 Мерц Фарма Гмбх Унд Ко. Кгаа Новые циклические и ациклические пропеноны для лечения заболеваний цнс
US20060105967A1 (en) 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Flavone derivatives as TNFalpha inhibitors or antagonists
WO2006076318A1 (en) 2005-01-12 2006-07-20 Aventis Pharmaceuticals Inc. Monopotassium salt of an ikb kinase inhibitor
AU2006204699B2 (en) 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
CA2593482A1 (en) 2005-01-14 2006-07-20 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
JP2008537684A (ja) 2005-01-24 2008-09-25 ニューロシステック コーポレイション 内耳およびその他の組織へ治療薬および/またはその他の薬剤を送達するための装置および方法
AU2006208042A1 (en) 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
US20060221197A1 (en) 2005-03-30 2006-10-05 Jung Edward K Image transformation estimator of an imaging device
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
EP1858865B1 (en) 2005-03-10 2009-09-16 Pfizer Inc. Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds
US7312233B2 (en) 2005-03-14 2007-12-25 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EA200701745A1 (ru) 2005-03-17 2008-06-30 Пфайзер, Инк. Циклопропанкарбоксамидные производные
CA2600282A1 (en) 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
ES2382876T3 (es) 2005-05-31 2012-06-14 Pfizer, Inc. Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
US20070021352A1 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP1928439A4 (en) 2005-09-26 2009-04-29 Piedmont Pharmaceuticals Llc METHOD FOR THE TREATMENT AND PREVENTION OF OTITIS MEDIA WITH CHEMICAL PENETRATION AMPLIFIERS TO FACILITATE THE TRANSMEMBRANOESE DRUG DELIVERY IN THE MIDDLE EAR
CN101272807A (zh) 2005-09-26 2008-09-24 皮埃蒙特医药品有限公司 使用非离子表面活性剂促进跨膜药物输送到中耳治疗和预防中耳炎的方法
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US20070110788A1 (en) 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP4273235B2 (ja) * 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン4阻害薬
TW200819458A (en) 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2008049196A1 (en) 2006-10-27 2008-05-02 Iomedix Development International Srl Composition for improving blood cholesterol levels
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
JP2010525073A (ja) 2007-04-23 2010-07-22 ハウス イアー インスティトゥート 代謝型グルタミン酸受容体7の調節による老人性難聴の治療及び/又は予防
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
WO2009142719A2 (en) 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
EP2296632A4 (en) 2008-07-14 2014-11-12 Otonomy Inc COMPOSITIONS AND METHODS FOR MODULATING CONTROLLED RELEASE APOPTOSIS FOR THE TREATMENT OF OTIC DISORDERS
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
WO2010011605A2 (en) 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
CA2751761A1 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
JP5376987B2 (ja) 2009-02-18 2013-12-25 キヤノン株式会社 レチクルの製造方法、および面形状計測装置
JP6395687B2 (ja) * 2015-10-16 2018-09-26 株式会社カプコン 映像生成方法、映像生成プログラムおよび映像生成装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107791B1 (en) * 1998-09-04 2007-05-30 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2551359C1 (ru) * 2013-11-28 2015-05-20 Олег Ростиславович Михайлов Наноразмерная слабо закристаллизованная модификация 4-метил-n-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2751697C1 (ru) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Средство для лечения отитов наружного слухового прохода у собак

Also Published As

Publication number Publication date
AU2009239429A1 (en) 2009-10-29
KR20190026056A (ko) 2019-03-12
US10751281B2 (en) 2020-08-25
US11123286B2 (en) 2021-09-21
WO2009132050A3 (en) 2010-01-14
CN102014957A (zh) 2011-04-13
WO2009132050A2 (en) 2009-10-29
KR20210107137A (ko) 2021-08-31
KR20130097813A (ko) 2013-09-03
IL208549A0 (en) 2010-12-30
JP2016026218A (ja) 2016-02-12
US20160243028A1 (en) 2016-08-25
IL208549A (en) 2017-04-30
IL251768B (en) 2022-02-01
JP6296565B2 (ja) 2018-03-20
JP2019085423A (ja) 2019-06-06
KR101449785B1 (ko) 2014-10-14
US20220040096A1 (en) 2022-02-10
US10272034B2 (en) 2019-04-30
US20240358634A1 (en) 2024-10-31
EP2278999C0 (en) 2025-01-29
BRPI0910850B1 (pt) 2022-06-14
US20160228357A1 (en) 2016-08-11
JP2014058557A (ja) 2014-04-03
US20190307678A1 (en) 2019-10-10
EP2278999A2 (en) 2011-02-02
JP2017119723A (ja) 2017-07-06
KR20200035508A (ko) 2020-04-03
EP2278999B1 (en) 2025-01-29
US20160095902A1 (en) 2016-04-07
JP6544535B2 (ja) 2019-07-17
CA2721927C (en) 2014-01-28
CN104491864A (zh) 2015-04-08
CA2721927A1 (en) 2009-10-29
KR20160029870A (ko) 2016-03-15
JP2011518195A (ja) 2011-06-23
KR102340754B1 (ko) 2021-12-16
JP2020147610A (ja) 2020-09-17
CN102014957B (zh) 2014-12-10
US11123285B2 (en) 2021-09-21
AU2009239429B2 (en) 2013-08-29
RU2010147298A (ru) 2012-05-27
EP2278999A4 (en) 2015-04-22
HK1209055A1 (en) 2016-03-24
MX2010011545A (es) 2011-04-11
US20090306225A1 (en) 2009-12-10
WO2009132050A9 (en) 2011-02-03
US9132087B2 (en) 2015-09-15
BRPI0910850A2 (pt) 2020-08-25
JP6147653B2 (ja) 2017-06-14
IL251768A0 (en) 2017-06-29
KR20100135299A (ko) 2010-12-24
US20200230051A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
RU2010147298A (ru) Фармацевтическая композиция для лечения ушных заболеваний
JP2019524657A5 (cg-RX-API-DMAC7.html)
HRP20140920T1 (hr) Farmaceutski pripravci za lijeäśenje poremeä†aja unutrašnjeg uha
JP5784189B2 (ja) 蝸牛性耳鳴の治療用1−アミノ−アルキルシクロヘキサン誘導体
CA2959404A1 (en) Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
RU2010150863A (ru) Фармацевтическая композиция для лечения ушных заболеваний
US11162071B2 (en) Compositions and methods for generating hair cells by upregulating JAG-1
RU2014114499A (ru) Препараты {2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил}амида циклопропанкарбоновой кислоты
WO2015031393A1 (en) Treatment of pediatric otic disorders
US20220175776A1 (en) Combination of chir99021 and valproic acid for treating hearing loss
JP2012148995A (ja) 難聴疾患の予防又は治療剤
JP2010506937A (ja) スピロヘータ及びその他の偏性細胞内細菌性疾患の治療及び管理のために免疫調節化合物を用いる方法及び組成物
RU2013157834A (ru) Композиции для подкожного введения физиологически активных средств
US20200080055A1 (en) Compositions and methods for generating hair cells by upregulating pi3k
US20220127568A1 (en) Compositions and methods for generating hair cells by inhibiting epigenetic targets
Wenzel et al. Effects of extracochlear gacyclidine perfusion on tinnitus in humans: a case series
JP6084931B2 (ja) ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
TW201141468A (en) Neramexane for the treatment or prevention of inner ear disorders
JPWO2006003910A1 (ja) メニエール病の予防および/または治療剤
EP3920885A1 (en) Valproic acid compounds and wnt agonists for treating ear disorders
JP2015515971A5 (cg-RX-API-DMAC7.html)
WO2011049954A2 (en) Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders
JP2019513780A (ja) 耳疾患の処置における使用のための(+)−アザセトロン
Worsøe et al. Intratympanic steroid prevents long-term spiral ganglion neuron loss in experimental meningitis
JP5978472B2 (ja) 耳鳴患者の治療用の薬剤

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200422